Six-year experience: long-term disease control outcomes for partial breast irradiation using MammoSite balloon brachytherapy
Presented at the 31st Annual San Antonio Breast Cancer Symposium, December 10–14, 2008, San Antonio, TX.
Received 16 February 2009; received in revised form 11 March 2009 published online 19 October 2009.
Abstract
Background
This report describes estimated 4-year tumor bed and ipsilateral breast recurrence-free intervals, event-free survival, disease-specific survival, and overall survival in a cohort of MammoSite brachytherapy (MBT) patients with mature follow-up treated at a single institution over a 6-year period.
Methods and Materials
An analysis of MBT cases was performed by using a prospectively collected quality-assurance database, departmental chart review, and electronic medical records. Patient-, tumor-, treatment-, and outcome-specific data were extracted and recorded into a research database. Patients were eligible for inclusion in this analysis if they were at least 6 months post-MBT.
Results
From May 2002 through March 2008, 111 MBT patients have been treated and were eligible for the present analysis. With a median follow-up of 46 months, the estimated 4-year outcomes for the entire cohort were tumor bed control 99%, ipsilateral breast control 95%, event-free survival 88%, disease-specific survival 97%, and overall survival 92%.
Conclusions
The present study shows low rates of local and ipsilateral breast disease failure in a well-defined cohort of MBT patients with mature follow-up.
ABSTRACT